Enovis (ENOV) Projected to Post Earnings on Thursday

Enovis (NYSE:ENOV) is projected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Enovis to post earnings of $0.82 per share and revenue of $572.1180 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The firm had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.98 EPS. On average, analysts expect Enovis to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Enovis Stock Performance

NYSE:ENOV traded up $0.62 during trading on Tuesday, reaching $23.96. The company’s stock had a trading volume of 414,912 shares, compared to its average volume of 1,001,878. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -1.16 and a beta of 1.41. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The firm has a 50 day moving average of $23.70 and a 200-day moving average of $25.93. Enovis has a 12 month low of $21.00 and a 12 month high of $37.85.

Insider Buying and Selling

In related news, insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction on Friday, February 27th. The stock was acquired at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders bought 5,000 shares of company stock valued at $121,983. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENOV. FORA Capital LLC bought a new position in Enovis in the 2nd quarter valued at $304,000. Mackenzie Financial Corp boosted its holdings in Enovis by 31.3% in the 3rd quarter. Mackenzie Financial Corp now owns 9,555 shares of the company’s stock valued at $290,000 after purchasing an additional 2,275 shares during the period. Gabelli Funds LLC bought a new position in Enovis in the 2nd quarter valued at $289,000. Creative Planning bought a new position in Enovis in the 3rd quarter valued at $274,000. Finally, Empowered Funds LLC boosted its holdings in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. Institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ENOV. UBS Group restated a “buy” rating and issued a $50.00 price objective on shares of Enovis in a research note on Monday, January 5th. BTIG Research increased their target price on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday. William Blair initiated coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Needham & Company LLC increased their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.